According to ARRS’ American Journal of Roentgenology (AJR), percutaneous image-guided microwave and cryoablation allow for repeat minimally invasive treatment of sarcoma lung metastases with manageable, predominantly mild complications.
“High primary technical success, local control, and overall survival support microwave and cryoablation for treating sarcoma lung metastases,” concluded 2019 ARRS Scholar Florian J. Fintelmann of Massachusetts General Hospital and Harvard Medical School.
Noting that ablation modality and tumour location did not affect local progression (p>.05), “treatment failure was low, especially for small tumours,” Fintelmann continued.
Fintelmann and colleagues’ retrospective cohort study included 27 patients (16 women, 11 men; median age, 64 years; Eastern Cooperative Oncology Group performance score, 0–2) who underwent 39 percutaneous CT-guided ablation sessions (21 microwave, 18 cryoablation; 1–4 sessions per patient) to treat 65 sarcoma lung metastases (median 1 tumour per patient, range 1–12; median tumour diameter 11 mm, range 5–33 mm; 25% non-peripheral) from 2009 to 2021.
Estimated 2-year local control rate for microwave versus cryoablation was 95% and 98% for tumours ≤1 cm, and 62% and 79% for tumours >1 cm.
Additionally, tumour size ≤1 cm was associated with decreased cumulative incidence of local progression (p=.048).
Reiterating the suitability of both percutaneous microwave and cryoablation for treating tumours ≤1 cm, whether peripheral or non-peripheral, “complications, if they occur, are not life-threatening,” the authors of this AJR article added.